



# Scalable Phenotyping for Safety Outcomes Using Electronic Health Record Data

Brian D. Williamson, PhD

Kaiser Permanente Washington Health Research Institute



## Disclaimer

The views expressed in this presentation represent those of the presenters and do not necessarily represent the official views of the U.S. FDA.

# Acknowledgments

## Sentinel Advanced Phenotyping Framework and Scalable Natural Language Processing (NLP) Teams

### **FDA**

- Adebola Ajao
- Robert Ball
- Steven Bird
- Sara Karami
- Yong Ma
- Michael Nguyen
- Danijela Stojanovic
- Sanrat Wittayanukorn
- Mingfeng Zhang
- Yueqin Zhao

### **Harvard Pilgrim**

### **Health Care Institute**

- Adee Kennedy
- Judy Maro
- Elizabeth Messenger-Jones
- Kathleen Shattuck
- Mayura Shinde
- Darren Toh

### **Kaiser Washington**

- Maralyssa Bann
- Will Bowers
- David Carrell
- David Cronkite
- James Floyd
- Monica Fujii
- Vina Graham
- Kara Haugen
- Eric Johnson
- Ron Johnson
- Ann Kelley
- Linda Kiel
- Jennifer Nelson
- Arvind Ramaprasan
- Mary Shea
- Brian Williamson
- Jing Zhou

### **Univ. of Washington**

- Patrick Heagerty

### **Kaiser Northwest**

- Andrew Felcher
- Brian Hazlehurst
- Denis Nyongesa
- Daniel Sapp
- Matthew Slaughter

### **Putnam Data Sciences**

- Susan Gruber

### **Vanderbilt University**

- Cosmin (Adi) Bejan
- Michael Matheny
- Joshua Osmanski
- Daniel Park
- Joshua Smith
- Dax Westerman
- Robert Winter

### **Univ. of Michigan**

- Xu Shi

### **HealthCore**

- Kevin Haynes

### **Duke University**

- Keith Marsolo

### **Brigham and Women's Hospital, Harvard**

- Rishi Desai
- William Feldman
- Shamika More
- Shirley Wang

### **Univ. of Pennsylvania**


- Kevin Johnson

### **Indiana University**

- David Aronoff


# Motivation

- Goal: improve safety surveillance using observational data
- Active Risk Identification and Analysis (ARIA) system:



# Motivation

## When is the ARIA Process Needed?



**ARIA must be considered before a sponsor PMR can be issued**

# ARIA Sufficiency

- ARIA is **sufficient** when:
  - Outcome & exposure of interest, covariates can be identified from data
  - Methods can assess exposure-related risk *with satisfactory precision*
- 2016—2018: ARIA **insufficient** for **45 of 89** drug/outcome pairs
  - Inadequate identification of outcome: 38 pairs

Example ARIA **sufficient**\* outcomes:

- GI bleeding
- Heart failure
- Lymphoma
- Major adverse cardiac events (MACE)
- Myocardial infarction
- Multiple sclerosis relapse
- Non-melanoma skin cancer
- Seizure
- Stroke

Example ARIA **insufficient**\* outcomes:

- **Acute pancreatitis**
- **Anaphylaxis**
- Drug-induced liver injury
- Fatal MACE
- Malignancies (several)
- Nerve injury
- Suicide or suicidal ideation


# Improving ARIA Sufficiency

- Our focus: outcome identification (phenotyping)
- Key considerations:
  - Gold-standard data creation
  - Feature engineering
  - Model development
  - Model evaluation
- Challenge: traditional chart review **expensive** (in time and resources)
- Approach: a **general framework** for scalable phenotyping algorithms
- Case studies: acute pancreatitis, anaphylaxis, severe COVID-19

# Assessing Fitness for Purpose

Can a phenotyping effort succeed for the outcome of interest?


- Key considerations:
  - Downstream use of the predicted outcome
  - Ambiguity of the clinical condition (*clinical complexity*)
  - Ambiguity arising from healthcare data (*data complexity*)






# Clinical and Data Complexity: Anaphylaxis

- Clinical complexity:
  - Diagnosis complex, relies on subjective assessment of signs and symptoms
  - 20% of charts at KPWA identified as “difficult” or discordant across two MD reviewers
  - Event often does not occur under direct observation
- Data complexity:
  - Relevant information captured in chart notes



# Clinical and Data Complexity: Acute Pancreatitis

- Clinical complexity:
  - Established events criteria include pain, imaging results
- Data complexity:
  - Relevant information captured in ICD-10 diagnosis code and serum lipase laboratory value\*




# Gold-standard Data Creation

- Goal: identify true cases and controls for algorithm training
- Challenge: **limited resources** (time, personnel)
- Best practices:
  - Chart abstraction guidelines reflect clinical diagnostic criteria
  - Clinician oversight of chart abstractors
  - Dual review of samples to assess replicability
  - **Use K-fold cross-validation**
- Future work:
  - Can NLP-assisted methods reduce review time?
  - Can **surrogate outcomes** be incorporated in model training?


# Feature Engineering

- Goal: identify useful features from the EHR
- Challenges:
  - Limited resources (time, personnel)
  - Local vocabulary **reduces generalizability**
- Best practices:
  - Incorporate clinical and domain knowledge
  - Engineer **many features**
  - Consider **manual and automated** approaches
- Future work:
  - Can automated approaches capture all relevant relationships?
  - Automated approaches with **acute outcomes?**




# Model Development and Evaluation

- Goal: construct a **useful** prediction model
- Challenges:
  - Performance **constrained by clinical and data complexity**
  - Evaluation requires gold-standard outcomes
- Best practices:
  - Incorporate domain knowledge
  - Consider a **large, diverse** set of candidate prediction algorithms (including **machine learning**)
  - Evaluate performance using K-fold cross-validation
  - Consider many performance metrics
  - Final algorithm choice guided by downstream **performance, replicability, generalizability**
- Future work:
  - Under what conditions can models be **transported to new settings** without additional gold-standard evaluation?




# Selected Results

## Predicting Anaphylaxis



## Predicting Symptomatic COVID-19



# Closing Thoughts

All aspects of phenotyping can be improved by

- Considering data and clinical complexity
- Incorporating domain knowledge
- Using a wide variety of tools (including machine learning), with proper evaluation

Our framework provides guidelines for **fully incorporating EHR data** into phenotyping analyses



## Thank You

### **Brian Williamson**

Assistant Investigator, Biostatistics Division

Kaiser Permanente Washington Health Research Institute

Contact: [brian.d.williamson@kp.org](mailto:brian.d.williamson@kp.org)